Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site

Molecular Pharmacology

Volumn 52, Issue 5, 1997, Pages 839-845

  Hasinoff, Brian B ^a,d   Creighton, Andrew M ^c   Kozlowska, Hanna ^a   Thampatty, Padmakumari ^b   Allan, William P ^b   Yalowich, Jack C ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; BIS(DIOXOPIPERAZINE) DERIVATIVE; ETOPOSIDE; GYRASE INHIBITOR; MITINDOMIDE; RAZOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; DRUG BINDING; DRUG INFORMATION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0030733491     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.5.839     Document Type: Article

References (36)

1. Narayanan, V. L. Strategy for the discovery and development of novel anticancer agents, in Structure-Activity Relationships of Anti-Tumour Agents (D. N. Reinhoudt, T. A. Connors, H. M. Pinedo, and L. W. van de Poll, eds.). Martinus Nijhoff, The Hague, 5-22 (1983).
2. Neighbors, R. P., and J. R. Riden, inventors. Chevron Research, assignee. Use of a tricyclodecene-3,4,7,8-tetracarboxylic acid diimide as an anti-murine tumor agent. U.S. Patent 4,877,806 (1989).
3. Deutsch, H. M., L. T. Gelbaum, M. McLaughlin, T. J. Fleischmann, L. L. Earnhart, R. D. Haugwitz, and L. H. Zalkow. Synthesis of congeners and prodrugs of the benzene maleimide photoadduct, mitindomide, as potential antitumor agents. J. Med. Chem. 29:2164-2170 (1986).
4. Moore, D. J., G. Powis, D. C. Melder, H. M. Deutsch, and L. H. Zalkow. Cross-linking of DNA by diimide antitumor agents and the relationship to cytotoxicity in A204 rhabdomyosarcoma cells. J. Cell. Pharmacol. 1:103-108 (1990).
5. 2,5]dec-9-ene-3,4,7,8-tetracarboxylic acid diimide: formulation and stability studies. J. Pharm. Sci. 75:301-303 (1986).
6. Sampedro, F., J. Partika, P. Santalo, A. M. Molins-Pujol, J. Bonal, and R. J. Perez-Soler. Liposomes as carriers of different new lipophilic antitumor drugs: a preliminary report. J. Microencapsul. 11:309-318 (1994).
7. Zhubanov, B. A., G. I. Boiko, K. A. Abdulin, M. B. Umerzakova, and Z. K. Ibraeva. Tricyclodecenetetracarboxydiimides, and their antitumor activity. Khim.-Farm. Zh. 25:43-44 (1991).
8. Haugwitz, R. D., V. Narayanan, L. H. Zalkow, H. M. Deutch, and L. Gelbaum, inventors. United States of America, assignee. Substituted N-methyl derivatives of mitindomide. U.S. Patent 4,803,202 (1984).
9. Haugwitz, R. D., V. L. Narayanan, L. H. Zalkow, and H. M. Deutsch. Formaldehyde derivatives of mitindomide. United States of America, assignee. U.S. Patent 4,670,461 (1987).
10. Umprayn, K., V. J. Stella, and C. M. Riley. Stability indicating assay for fetindomide (NSC 373965), a potential prodrug of mitindomide (NSC 284356), employing high-performance liquid chromatography. J. Pharm. Biomed. Anal. 5:675-685 (1987).
11. Ishida, R., T. Miki, T. Narita, R. Yui, M. Sato, K. R. Utsumi, K. Tanabe, and T. Andoh. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 51:4909-4916 (1991).
12. Hasinoff, B. B., T. I. Kuschak, J. C. Yalowich, and A. M. Creighton. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem. Pharmacol. 50:953-958 (1995).
13. Creighton, A. M., K. Hellmann, and S. Whitecross. Antitumour activity in a series of bisdiketopiperazines. Nature (Lond.) 22:384-385 (1969).
14. Speyer, J. L., M. D. Green, A. Zeleniuch-Jacquotte, J. C. Wernz, M. Rey, J. Sanger, E. Kramer, V. Ferrans, H. Hochster, M. Meyers, R. H. Blum, F. Feit, M. Attubato, W. Burrows, and F. M. Muggia. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10:117-127 (1992).
15. Buss, J. L., and B. B. Hasinoff. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40:86-95 (1993).
16. Corbett, A. H., and N. Osheroff. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 6:585-597 (1993).
17. Berger, J. M., S. J. Gamblin, S. C. Harrison, and J. C. Wang. Structure and mechanism of DNA topoisomerase II. Nature (Lond.) 379:225-232 (1996).
18. Bojanowski, K., S. Lelievre, J. Markovits, J. Couprie, A. Jacquemin-Sablon, and A. K. Larsen. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA 89:3025-3029 (1992).
19. Drake, F. H., G. A. Hofman, S. M. Mong, J. O. Bartus, R. P. Hertzberg, R. K. Johnson, M. R. Mattern, and C. K. Mirabelli. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 49:2578-2583 (1989).
20. Jensen, P. B., P. S. Jensen, E. J. F. Demant, E. Friche, B. S. Sorensen, M. Sehested, K. Wassermann, L. Vindelov, O. Westergaard, and H. H. Hansen. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res. 51:5093-5099 (1991).
21. Hasinoff, B. B., T. I. Kuschak, A. M. Creighton, C. L. Fattman, W. P. Allan, P. Thampatty, and J. C. Yalowich. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem. Pharmacol. 53:1843-1853 (1997).
22. Sehested, M., P. B. Jensen, B. S. Sorensen, B. Holm, E. Friche, and E. J. F. Demant. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol. 46:389-393 (1993).
23. Fattman, C., W. P. Allan, B. B. Hasinoff, and J. C. Yalowich. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem. Pharmacol. 52: 635-642 (1996).
24. Hasinoff, B. B., J. C. Yalowich, Y. Ling, and J. L. Buss. The effect of dexrazoxane (ICRF-187) on doxorubicin and daunorubicin-mediated growth inhibition of Chinese hamster ovary (CHO) cells. Anticancer Drugs 7:558-567 (1996).
25. Kenwrick, S. J. Studies on the mechanism of induced resistance to antitumour agent ICRF 159 in mammalian cell lines. Ph.D. thesis. University of London, London (1984).
26. Creighton, A. M., J. Long, and S. J. Kenwrick. A comparative study of the properties of the tumour-inhibitory photosynthetic benzene-maleimide adduct (NSC 284, 356 and ICRF 159). Imperial Cancer Res. Fund Sci. Report-1983. 143-144 (1984).
27. Sahai, B. M., and J. G. Kaplan. A quantitative decatenation assay for type II topoisomerases. Anal. Biochem. 156:364-379 (1986).
28. Ritke, M. K., D. Roberts, W. P. Allan, J. Raymond, V. V. Bergoltz, and J. C. Yalowich. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. Br. J. Cancer 69:687-697 (1994).
29. Burkert, U., and N. L. Allinger. Molecular Mechanics. ACS Monograph 177. American Chemical Society, Washington, D. C. (1982).
30. Clarke, D. J., R. T. Johnson, and C. S. Downes. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J. Cell Sci. 105:563-569 (1993).
31. Hempel, A., N. Camerman, and A. Camerman. Stereochemistry of the antitumor agent 4,4′-(1,2-propanediyl)bis(4-piperazine-2,6-dione): crystal and molecular structures of the racemate (ICRF-159) and a soluble enantiomer (ICRF-187). J. Am. Chem. Soc. 105:3453-3456 (1982).
32. 8. Acta Crystallogr. Sect. C 40:1925-1927 (1984).
33. Pettit, G. R., K. D. Paull, C. L. Herald, D. L. Herald, and J. R. Riden. Antineoplastic agents. 90. The structure of the benzene-maleimide photosynthetic product (mitindomide). Can. J. Chem. 61:2291-2294 (1983).
34. Kenwrick, S. J., and A. M. Creighton. Isolation and characterization of a subline of CHO cells with induced resistance to ICRF 159. Br. J. Cancer 46:504-505 (1982).
35. Roca, J., R. Ishida, J. M. Berger, T. Andoh, and J. C. Wang. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA 91:1781-1785 (1994).
36. Roca, J., and J. C. Wang. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833-840 (1992).